The biopharma contract developer and manufacturer Catalent $CTLThas swooped in to buy out Juniper Pharmaceuticals $JNP for $133 million, adding their services with an eye to amping up its early drug development offerings in the UK.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,